A customized messenger RNA (mRNA) cancer vaccine being developed by Moderna and Merck plus the checkpoint inhibitor Keytruda (pembrolizumab) reduced the risk for metastasis in people with high-risk advanced melanoma, according to updated study results presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Clinical Trials
Cancer Vaccine mRNA-4157 Improves Recurrence-Free Survival for Patients With High-Risk Melanoma
Adjuvant treatment with mRNA-4157 plus pembrolizumab led to a 65% reduction in the risk of distant metastasis or death compared with pembrolizumab alone, among patients with resected melanoma at high risk of recurrence, according to findings from the phase 2 KEYNOTE-942 trial (NCT03897881) that were presented at the 2023 ASCO Annual Meeting.
Melanoma-Specific Survival Longer With Nivolumab Plus Relatlimab Combined Treatment
Nivolumab plus relatlimab showed a clear benefit in progression-free survival, overall survival and objective response rate.
New Treatment Strategies and Therapies in Pediatric Dermatologic Conditions
Treating rare or even common dermatologic conditions in pediatric patients requires expert knowledge as well as compassion. Attendees at the 2023 Fall Clinical Dermatology Conference for PAs and NPs were eager to attend Adelaide Hebert’s, MD, session, “What is New in Pediatric Dermatology.”